Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced the consummation of a strategic asset transfer agreement with Lunai Bioworks, Inc., granting worldwide rights to its nose-to-brain (N2B) delivery system intellectual property within the biodefense and Alzheimer's disease fields. In exchange, Oncotelic received $12.5 million in Series B convertible preferred stock. The agreement establishes an initiative focused on CNS-targeted therapeutics while supporting the company's strategy to monetize its portfolio and retain control of core assets.
The N2B platform enables intranasal delivery directly to the central nervous system, bypassing the blood-brain barrier to support rapid therapeutic action and targeted neurological engagement. This technology has applications in biodefense medical countermeasures and neurodegenerative conditions. Under the agreement, Lunai Bioworks will develop the platform within the specified fields, while Oncotelic retains rights for other indications, including Parkinson's disease and sexual dysfunction, leveraging internal expertise in CNS therapeutics and biodefense.
This transaction is significant for the industry as it demonstrates a viable pathway for small biopharmaceutical companies to monetize specialized platforms while retaining value in core assets. For leaders in business and technology, the deal highlights the growing importance of targeted drug delivery systems, particularly those addressing neurological conditions—a area of high unmet need. The N2B technology's ability to bypass the blood-brain barrier could revolutionize treatment for Alzheimer's and biodefense applications, potentially reducing side effects and improving efficacy.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products. The company's mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. The company also leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.
Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens Oncotelic's position in oncology and rare disease therapeutics.
For investors, the asset transfer represents a strategic move to unlock value from non-core assets while maintaining focus on key therapeutic areas. The $12.5 million in preferred stock provides Oncotelic with capital without diluting common shareholders, and the retained rights to Parkinson's and sexual dysfunction indications offer upside potential. The deal also underscores the increasing collaboration between small biotechs and specialized development companies to advance promising technologies.
To view the full press release, visit https://ibn.fm/IWUpe. For the latest news and updates relating to OTLC, visit the company's newsroom at https://ibn.fm/OTLC.
